Anti-epidermal growth factor receptor monoclonal antibodies as potential anti-cancer agents |
| |
Authors: | John Mendelsohn |
| |
Affiliation: | Memorial Sloan-Kettering Cancer Center, New York, NY 10021, U.S.A. |
| |
Abstract: | The EGF receptor is a potential target for antitumor therapy, because it is expressed at high levels on many human tumor cells and appears to be involved in autocrine stimulation of cell growth in a number of experimental studies. Anti-EGF receptor MAbs, which block ligand binding, can prevent the growth in culture of cells that are stimulated by EGF or TGF-. Growth of human tumor xenografts bearing high levels of EGF receptors is also inhibited. A Phase I trial in patients with squamous cell carcinoma of the lung has demonstrated the capacity of a single dose of 120 mg anti-EGF receptor MAb to localize in such tumors and to achieve saturating concentrations in the blood for more than 3 days, without causing toxicity. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|